Delphi Diagnostics Inc.TM is a Texas-based start-up, incorporated in 2016, with an exclusive license to intellectual property from Dr. Fraser Symmans’ breast cancer research at the University of Texas MD Anderson Cancer Center in Houston.
Delphi’s team of professionals brings extensive experience in developing and validating diagnostics from the laboratory to the patient. The company’s first pipeline diagnostic will be the Endocrine Activity IndexTM (also known as EAITM)for hormone receptor-positive breast cancer.